CELL AND GENE THERAPY INSIGHTS

December 2022 Issue

Volume 8 Issue 11

Cell and Gene Therapy Insights Volume 8 Issue 11
Download PDF

Featuring

Issue Spotlight: Tools of tomorrow
Other articles
Webinar

SPOTLIGHT

Tools of tomorrow

Expert Insight

Exosomes: next generation vectors for drug delivery & gene therapy

Exosomes: next generation vectors for drug delivery & gene therapy

Jess Morhayim, Jeroen de Vrij
12 December 2022
Read
Harnessing the power of design of experiments for cell therapy research & process development

Harnessing the power of design of experiments for cell therapy research & process development

Sean O’Farrell
30 November 2022
Read

Innovator Insight

Viral vector manufacturing process: addressing bottlenecks with innovative solutions

Viral vector manufacturing process: addressing bottlenecks with innovative solutions

Rachel Legmann
14 December 2022
Read

Interview

Leveraging cellular immunotherapy at the cutting edge of autoimmune disease R&D

Leveraging cellular immunotherapy at the cutting edge of autoimmune disease R&D

Silvio Manfredo-Vieira
12 December 2022
Read
Key priorities for cell & gene therapy manufacturing evolution in 2023 & beyond

Key priorities for cell & gene therapy manufacturing evolution in 2023 & beyond

David DiGiusto
28 November 2022
Read

Regulatory Insight

How to secure & standardize your cell expansion

How to secure & standardize your cell expansion

Paula Villaescusa Sánchez, Anette Brass
26 January 2023
Read

FastFacts

Cell collection in cell therapy — quality matters

Cell collection in cell therapy — quality matters

Sara Lewandowski
14 December 2022
Read

Short Communication

Thinking ahead: developing biosynthetic blood to anticipate donor drought

Thinking ahead: developing biosynthetic blood to anticipate donor drought

A S Goldman, S Kilpatrick, M Madrid et al.
3 January 2023
Read

Journal articles

Perspective

The parent–child IND approach: an interpretation of FDA’s guidance on studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

The parent–child IND approach: an interpretation of FDA’s guidance on studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Timmothy Taps
3 January 2023
Read

Innovator Insight

Lentiviral titer determination: rapid & robust molecular methods suitable for validation

Lentiviral titer determination: rapid & robust molecular methods suitable for validation

Unnati Dev
22 February 2023
Read
RCA-free production of third generation adenoviral vectors

RCA-free production of third generation adenoviral vectors

Nico Scheer, Helmut Kewes, Ulrich Kettling
15 December 2022
Read
Walking on thin ice: controlled freezing & thawing of pharmaceutical active molecules

Walking on thin ice: controlled freezing & thawing of pharmaceutical active molecules

Barbara Fischer
14 December 2022
Read

Commentary

Key considerations & challenges in developing flow cytometry assays for cell & gene therapy products

Key considerations & challenges in developing flow cytometry assays for cell & gene therapy products

Ajit Kamath
12 December 2022
Read

Interview

Sharing personal experience on the development of cell therapy technology, quality & analytics since the 1990s & the application of ‘phase appropriate GMPs’ to cell therapy development

Sharing personal experience on the development of cell therapy technology, quality & analytics since the 1990s & the application of ‘phase appropriate GMPs’ to cell therapy development

Amnon Eylath
19 December 2022
Read

FastFacts

Find your competitive advantage through custom buffer formulations for CAR-T manufacturing

Find your competitive advantage through custom buffer formulations for CAR-T manufacturing

Benito Delgado
4 January 2023
Read
Viral vector production guide part 1: choosing the correct grade for your gene therapy application

Viral vector production guide part 1: choosing the correct grade for your gene therapy application

James Cody
20 December 2022
Read
Viral vector production guide part 2: considerations of scaling up GMP

Viral vector production guide part 2: considerations of scaling up GMP

Daniel Smith
20 December 2022
Read
Synergize your tools to generate process insights

Synergize your tools to generate process insights

Rohit Saklecha, Andres Castillo
15 December 2022
Read

Webinar Digest

Mycoplasma testing: regulatory guidance and strategies for cGMP cell and gene therapy manufacturing

Mycoplasma testing: regulatory guidance and strategies for cGMP cell and gene therapy manufacturing

Mike Brewer
15 December 2022
Read

Poster

Regulatory requirements and product attributes for cGMP viral vector production

Regulatory requirements and product attributes for cGMP viral vector production

Scott Cross, Shikha Mishra
19 December 2022
Read
Manufacturing considerations underpinning viral & non-viral platform selection

Manufacturing considerations underpinning viral & non-viral platform selection

A Hagerman, A Noyes, V Slepushkin et al.
15 December 2022
Read

Corrigendum

CORRIGENDUM to Purification of therapeutic & prophylactic mRNA by affinity chromatography

CORRIGENDUM to Purification of therapeutic & prophylactic mRNA by affinity chromatography

J Grinsted, J Liddell, E Bouleghlimat et al.
9 January 2023
Read

Webinars